J 2022

Cytokine-chemokine profiles in the hippocampus of patients with mesial temporal lobe epilepsy and hippocampal sclerosis

AULICKÁ, Štefánia, Katarína ČESKÁ, Jiří ŠÁNA, František SIEGL, Eva BRICHTOVÁ et. al.

Basic information

Original name

Cytokine-chemokine profiles in the hippocampus of patients with mesial temporal lobe epilepsy and hippocampal sclerosis

Authors

AULICKÁ, Štefánia (703 Slovakia, belonging to the institution), Katarína ČESKÁ (703 Slovakia, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution), František SIEGL (203 Czech Republic, belonging to the institution), Eva BRICHTOVÁ (203 Czech Republic, belonging to the institution), Hana OŠLEJŠKOVÁ (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Michal HENDRYCH (203 Czech Republic, belonging to the institution), Elleni MICHU (203 Czech Republic, belonging to the institution), Milan BRÁZDIL (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Igor NESTRAŠIL (203 Czech Republic)

Edition

Epilepsy Research, Amsterdam, Elsevier, 2022, 0920-1211

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.200

RIV identification code

RIV/00216224:14110/22:00129659

Organization unit

Faculty of Medicine

UT WoS

000820113600007

Keywords in English

Temporal lobe epilepsy; Hippocampal sclerosis; Pharmaco-resistant; Cytokine; Chemokine; Interleukin; Immune response; Epileptogenesis

Tags

International impact, Reviewed
Změněno: 2/2/2023 12:58, Mgr. Tereza Miškechová

Abstract

V originále

Purpose Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is the most common drug-resistant epilepsy. Despite major advances in epilepsy research, the epileptogenesis of the MTLE-HS is not well understood. The altered neuroimmune response is one of the pathomechanisms linked to progressive epileptogenesis in MTLE-HS, and understanding its role may help design future cures for pharmaco-resistant MTLE-HS. Here, the neuroimmune function was evaluated by the assessment of cytokine-chemokine profiles in brain samples from the hippocampus of patients with MTLE-HS. Methods Brain samples from patients with MTLE-HS collected during epileptosurgical resection (n = 21) were compared to those obtained from autopsy controls (n = 13). The typing of HS was performed according to ILAE consensus classification, and patients were additionally sorted into subgroups based on the severity of neuronal depletion (Wyler grading system). Differences between patients with MTLE-HS with and without a history of febrile seizures were also assessed. RNA was isolated from native samples, and real-time gene expression analysis of cytokine-chemokine profiles, i.e., levels of IL-1β, IL-6, IL-10, IL-18, CCL2, CCL3, CCL4, and STAT3, was carried out by qRT-PCR methodology. Results Upregulation of IL-1β (p = 0.001), IL-18 (p = 0.0018), CCL2 (p = 0,0377), CCL3 (p < 0.001), and CCL4 (p < 0.001) in MTLE-HS patients was detected when compared to the post-mortem hippocampal samples collected from autopsy controls. The STAT3 expression was higher in more severe neuronal loss and glial scaring determined by different Wyler grades in HS patients. Furthermore, cytokine-chemokine profiles were not different in MTLE-HS patients with or without febrile seizures. Conclusion The upregulation of specific cytokines and chemokines in MTLE-HS provides evidence that the neuroinflammatory process contributes to MTLE epileptogenesis. History of febrile seizures did not alter the immune profiles. Specific immune mediators and related immune pathways represent potential therapeutic targets for seizure control and pharmacoresistancy prevention in MTLE associated with hippocampal sclerosis.

Links

NU21-04-00305, research and development project
Name: Analýza transkriptomu a metylace DNA u pacientů s fokální kortikální dysplázií
Investor: Ministry of Health of the CR, Transcriptomics and DNA methylation analysis in patients with focal cortical dysplasia, Subprogram 1 - standard